1 40 1 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource 2023 Special Edition 3 - Oncology List Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Citation List Month 2023 SE3 - Oncology URL Address <a href="http://doi.org/10.1002/pbc.30115" target="_blank" rel="noreferrer noopener"> http://doi.org/10.1002/pbc.30115</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource The impact of clinical trial enrollment on specialty palliative care utilization in pediatric patients with high-grade gliomas Publisher An entity responsible for making the resource available Pediatric Blood and Cancer Date A point or period of time associated with an event in the lifecycle of the resource 2023 Subject The topic of the resource Humans; Child; palliative care; Palliative Care; Disease Progression; Palliative Care; Clinical Trials as Topic; clinical trial; Glioma; Glioma/therapy/pathology; high-grade glioma; pediatric brain tumor Creator An entity primarily responsible for making the resource Roberts HJ; Wang Y; Spruit JL; Taylor L; Franson AT Description An account of the resource BACKGROUND: Palliative care (PC) provides numerous benefits for children with cancer. Pediatric patients with high-grade glioma (HGG) are particularly well suited for early PC involvement given their high symptom burden and poor prognosis. However, studies continue to reveal that children with cancer, including HGG, have delayed PC involvement. We hypothesized that clinical trial enrollment may lead to a lack of or delay in PC involvement in this population. PROCEDURE: For each patient in our cohort of 43 pediatric patients with HGG, demographic, diagnostic, therapeutic, clinical trial enrollment, and PC information were collected. Statistical analysis was performed comparing PC characteristics between patients who did and did not enroll in a clinical trial. RESULTS: Seventy-two percent of patients had at least one visit with a PC provider. Fifty-six percent of patients enrolled in a clinical trial with HGG-directed therapy. Seventy-one percent of patients who enrolled in a clinical trial received specialty PC compared to 74% of non-trial participants (p = 1.000). Patients who enrolled in clinical trials received PC earlier in their disease course measured in days before death (mean = 177 days) compared to those who did not enroll (mean = 113 days, p = .180), though not statistically significant. CONCLUSIONS: The prevalence of clinical trial enrollment is high in patients with HGG and will likely increase as the genomic/epigenomic landscape of these tumors is better understood. As such, our data reassuringly suggest that trial participation does not interfere with the receipt of specialty PC in this population. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1002/pbc.30115" target="_blank" rel="noreferrer noopener">10.1002/pbc.30115</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s). 2023 2023 SE3 - Oncology Child Clinical Trial Clinical Trials as Topic Disease Progression Franson AT Glioma Glioma/therapy/pathology high-grade glioma Humans Palliative Care Pediatric Blood and Cancer Pediatric Brain Tumor Roberts HJ Spruit JL Taylor L Wang Y